Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Tocilizumab
Tocilizumab
Routinely available
NICE (TA375 (SMC 774/12))
27/03/2024
Indication
For the treatment of monotherapy in rheumatoid arthritis (RA) when biologic combination with methotrexate (MTX) is inappropriate [e.g. due to intolerance to MTX].
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Routinely available in line with local or regional guidance
Formulation
20mg/mL concentrate for solution for infusion
Comments
January 2016 - NICE MTA advice: SMC advice 774/12 is superseded by NICE TA375. Refer to pathway or local board guidelines for preferred formulation.
Link to Advice
Advice Published
26/01/2016